Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1995 Mar;58(3):271–273. doi: 10.1136/jnnp.58.3.271

Neuroleptic malignant syndrome.

P F Buckley, M Hutchinson
PMCID: PMC1073359  PMID: 7897404

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addonizio G., Susman V. L., Roth S. D. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 1986 Dec;143(12):1587–1590. doi: 10.1176/ajp.143.12.1587. [DOI] [PubMed] [Google Scholar]
  2. Adityanjee, Singh S., Singh G., Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry. 1988 Jul;153:107–111. doi: 10.1192/bjp.153.1.107. [DOI] [PubMed] [Google Scholar]
  3. Ames D., Wirshing W. C. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--a possible link? JAMA. 1993 Feb 17;269(7):869–870. [PubMed] [Google Scholar]
  4. Bristow M. F., Kohen D. How "malignant" is the neuroleptic malignant syndrome? BMJ. 1993 Nov 13;307(6914):1223–1224. doi: 10.1136/bmj.307.6914.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buckley P. F., Meltzer H. Y. Clozapine and NMS. Br J Psychiatry. 1993 Apr;162:566–566. doi: 10.1192/bjp.162.4.566a. [DOI] [PubMed] [Google Scholar]
  6. Buckley P., Freyne A., McCarthy A., Larkin C. Neuroleptic malignant syndrome--follow-up study. Ir J Med Sci. 1991 Feb;160(2):45–47. doi: 10.1007/BF02947643. [DOI] [PubMed] [Google Scholar]
  7. Caroff S. N., Mann S. C. Neuroleptic malignant syndrome. Med Clin North Am. 1993 Jan;77(1):185–202. doi: 10.1016/s0025-7125(16)30278-4. [DOI] [PubMed] [Google Scholar]
  8. Cohen O., Leibovici L., Mor F., Wysenbeek A. J. Significance of elevated levels of serum creatine phosphokinase in febrile diseases: a prospective study. Rev Infect Dis. 1991 Mar-Apr;13(2):237–242. doi: 10.1093/clinids/13.2.237. [DOI] [PubMed] [Google Scholar]
  9. DELAY J., PICHOT P., LEMPERIERE T., ELISSALDE B., PEIGNE F. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses]. Ann Med Psychol (Paris) 1960 Jan;118(1):145–152. [PubMed] [Google Scholar]
  10. Davis John M., Janicak Philip G., Sakkas Paul, Gilmore Cindy, Wang Zhengyu. Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. Convuls Ther. 1991;7(2):111–120. [PubMed] [Google Scholar]
  11. Friedman L. S., Weinrauch L. A., D'Elia J. A. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med. 1987 Aug;147(8):1495–1497. [PubMed] [Google Scholar]
  12. Garcia F. M., Duarte J., Perez A., Mataix A. L., Coria F., Clavería L. E. Low serum iron and neuroleptic malignant syndrome. Ann Pharmacother. 1993 Jan;27(1):101–102. doi: 10.1177/106002809302700125. [DOI] [PubMed] [Google Scholar]
  13. Gelenberg A. J., Bellinghausen B., Wojcik J. D., Falk W. E., Sachs G. S. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry. 1988 Apr;145(4):517–518. doi: 10.1176/ajp.145.4.517. [DOI] [PubMed] [Google Scholar]
  14. Goldwasser H. D., Hooper J. F., Spears N. M. Concomitant treatment of neuroleptic malignant syndrome and psychosis. Br J Psychiatry. 1989 Jan;154:102–104. doi: 10.1192/bjp.154.1.102. [DOI] [PubMed] [Google Scholar]
  15. Gurrera R. J., Chang S. S., Romero J. A. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. 1992 Feb;53(2):56–62. [PubMed] [Google Scholar]
  16. Haddad P. M. Neuroleptic malignant syndrome. May be caused by other drugs. BMJ. 1994 Jan 15;308(6922):200–200. doi: 10.1136/bmj.308.6922.200b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Heiman-Patterson T. D. Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am. 1993 Mar;77(2):477–492. doi: 10.1016/s0025-7125(16)30265-6. [DOI] [PubMed] [Google Scholar]
  18. Henderson V. W., Wooten G. F. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. 1981 Feb;31(2):132–137. doi: 10.1212/wnl.31.2.132. [DOI] [PubMed] [Google Scholar]
  19. Hermesh H., Aizenberg D., Lapidot M., Munitz H. Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am J Psychiatry. 1988 Nov;145(11):1431–1434. doi: 10.1176/ajp.145.11.1431. [DOI] [PubMed] [Google Scholar]
  20. Hermesh H., Aizenberg D., Weizman A. A successful electroconvulsive treatment of neuroleptic malignant syndrome. Acta Psychiatr Scand. 1987 Mar;75(3):237–239. doi: 10.1111/j.1600-0447.1987.tb02782.x. [DOI] [PubMed] [Google Scholar]
  21. Investigating young patients with dyspepsia. Lancet. 1989 Jan 7;1(8628):50–51. [PubMed] [Google Scholar]
  22. Keck P. E., Jr, Pope H. G., Jr, Cohen B. M., McElroy S. L., Nierenberg A. A. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989 Oct;46(10):914–918. doi: 10.1001/archpsyc.1989.01810100056011. [DOI] [PubMed] [Google Scholar]
  23. Keck P. E., Jr, Pope H. G., Jr, McElroy S. L. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry. 1991 Jul;148(7):880–882. doi: 10.1176/ajp.148.7.880. [DOI] [PubMed] [Google Scholar]
  24. Kellam A. M. The neuroleptic malignant syndrome, so-called. A survey of the world literature. Br J Psychiatry. 1987 Jun;150:752–759. doi: 10.1192/bjp.150.6.752. [DOI] [PubMed] [Google Scholar]
  25. Keyser D. L., Rodnitzky R. L. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med. 1991 Apr;151(4):794–796. [PubMed] [Google Scholar]
  26. Kish S. J., Kleinert R., Minauf M., Gilbert J., Walter G. F., Slimovitch C., Maurer E., Rezvani Y., Myers R., Hornykiewicz O. Brain neurotransmitter changes in three patients who had a fatal hyperthermia syndrome. Am J Psychiatry. 1990 Oct;147(10):1358–1363. doi: 10.1176/ajp.147.10.1358. [DOI] [PubMed] [Google Scholar]
  27. Levinson D. F., Simpson G. M. Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'. Arch Gen Psychiatry. 1986 Sep;43(9):839–848. doi: 10.1001/archpsyc.1986.01800090025005. [DOI] [PubMed] [Google Scholar]
  28. Mann S. C., Caroff S. N., Bleier H. R., Welz W. K., Kling M. A., Hayashida M. Lethal catatonia. Am J Psychiatry. 1986 Nov;143(11):1374–1381. doi: 10.1176/ajp.143.11.1374. [DOI] [PubMed] [Google Scholar]
  29. Nisijima K., Ishiguro T. Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study. Biol Psychiatry. 1993 Jan 1;33(1):45–48. doi: 10.1016/0006-3223(93)90277-k. [DOI] [PubMed] [Google Scholar]
  30. Nisijima K., Ishiguro T. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry. 1990 Feb 1;27(3):280–288. doi: 10.1016/0006-3223(90)90002-j. [DOI] [PubMed] [Google Scholar]
  31. O'Dwyer A. M., Sheppard N. P. The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome. Psychol Med. 1993 May;23(2):323–326. doi: 10.1017/s0033291700028415. [DOI] [PubMed] [Google Scholar]
  32. Rosebush P. I., Mazurek M. F. Serum iron and neuroleptic malignant syndrome. Lancet. 1991 Jul 20;338(8760):149–151. doi: 10.1016/0140-6736(91)90138-f. [DOI] [PubMed] [Google Scholar]
  33. Rosebush P. I., Stewart T. D., Gelenberg A. J. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry. 1989 Aug;50(8):295–298. [PubMed] [Google Scholar]
  34. Rosebush P. I., Stewart T., Mazurek M. F. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry. 1991 Nov;159:709–712. doi: 10.1192/bjp.159.5.709. [DOI] [PubMed] [Google Scholar]
  35. Rosebush P., Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989 Jun;146(6):717–725. doi: 10.1176/ajp.146.6.717. [DOI] [PubMed] [Google Scholar]
  36. Sakkas P., Davis J. M., Janicak P. G., Wang Z. Y. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27(3):381–384. [PubMed] [Google Scholar]
  37. Schibuk M., Schachter D. A role for catecholamines in the pathogenesis of neuroleptic malignant syndrome. Can J Psychiatry. 1986 Feb;31(1):66–69. doi: 10.1177/070674378603100114. [DOI] [PubMed] [Google Scholar]
  38. Schneiderhan M. E., Marken P. A. An atypical course of neuroleptic malignant syndrome. J Clin Pharmacol. 1994 Apr;34(4):325–334. doi: 10.1002/j.1552-4604.1994.tb02001.x. [DOI] [PubMed] [Google Scholar]
  39. Shalev A., Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986 Apr;73(4):337–347. doi: 10.1111/j.1600-0447.1986.tb02694.x. [DOI] [PubMed] [Google Scholar]
  40. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991 Jun;148(6):705–713. doi: 10.1176/ajp.148.6.705. [DOI] [PubMed] [Google Scholar]
  41. Velamoor V. R., Fernando M. L., Williamson P. Incipient neuroleptic malignant syndrome? Br J Psychiatry. 1990 Apr;156:581–584. doi: 10.1192/bjp.156.4.581. [DOI] [PubMed] [Google Scholar]
  42. Weller M., Kornhuber J. Clozapine rechallenge after an episode of 'neuroleptic malignant syndrome'. Br J Psychiatry. 1992 Dec;161:855–856. doi: 10.1192/bjp.161.6.855. [DOI] [PubMed] [Google Scholar]
  43. Weller M., Kornhuber J. Does clozapine cause neuroleptic malignant syndrome? J Clin Psychiatry. 1993 Feb;54(2):70–71. [PubMed] [Google Scholar]
  44. Wells A. J., Sommi R. W., Crismon M. L. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm. 1988 Jun;22(6):475–480. doi: 10.1177/106002808802200606. [DOI] [PubMed] [Google Scholar]
  45. White D. A. Catatonia and the neuroleptic malignant syndrome--a single entity? Br J Psychiatry. 1992 Oct;161:558–560. doi: 10.1192/bjp.161.4.558. [DOI] [PubMed] [Google Scholar]
  46. Woodbury M. M., Woodbury M. A. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992 Nov;31(6):1161–1164. doi: 10.1097/00004583-199211000-00028. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES